The Department of Health Covid Vaccination Dashboard
**Please see the HSCB Intranet for the latest Resources**
Please note some links will only work within the HSC network
Password is in the email ‘ COVID-19 & Flu Update 17 February’ from [email protected]
FAQs are correct on that date, subject to change as information develops
IF you are having difficulty you can access the GPNI PDF version below – this will be the latest version on the date specified by the file name.
COVID-19 Vaccination Pathways for Care Homes
To support access to the COVID-19 vaccine for those residents who may have missed the opportunity to be vaccinated within the initial roll out by HSC Trusts to Care Homes.
COVID-19 vaccination for people aged 16 & 17 in at risk group (priority group 6)
As the AstraZeneca vaccine used by GPs is only licenced for people aged 18 or over, 16 & 17 year olds identified as being Clinically Extremely Vulnerable or at risk will need to have Pfizer vaccine which is used in the vaccination centres.
When practices run their “Clinically Extremely Vulnerable” and “at risk” searches, they should identify patients aged 16 & 17 but not call them for vaccination in the practice.
Patients aged 16 & 17 should be actively encouraged to book for vaccination at the centres which are using Pfizer which is approved for people aged 16 or over. The portal now has an option for clinically extremely vulnerable and for clinically vulnerable aged 16 & 17.
HSC / Other NI Updates
Department of Health Updates
- JCVI has now recommended that as many people on the JCVI priority list as possible should be offered a first vaccine dose as the initial priority. The second dose of the AstraZeneca (Oxford) vaccine may be given between 4 to 12 weeks following the first dose.Printed patient leaflets are being distributed. Unfortunately these reference the original 3-4 week interval for the second dose. New versions will be printed and issued as soon as possible. Joint CMO Letter – Public Health rationale for close one priority strategy for COVID
- Updated advice for pregnant women and women who are breast feeding.
RCOG – COVID-19 vaccines and pregnancy
Public Health Agency Updates
Other NI Organisations
Communication / Public FAQs
The COVID-19 Vaccine Communication Handbook : This project tracks behavioural science evidence and advice about COVID-19 vaccine uptake.
HSCB is maintaining a FAQ for the public regarding the GP COVID-19 vaccine rollout and you may find this helpful where patients have questions. The link is http://www.hscboard.hscni.net/coronavirus/covid-19-vaccination-programme/.
The PHA also have some helpful FAQs for the public at https://www.publichealth.hscni.net/covid-19-coronavirus/northern-ireland-covid-19-vaccination-programme/covid-19-vaccination-programme
Report suspected side effects to medicines, vaccines or medical device and diagnostic adverse incidents used in coronavirus treatment to the Medicines and Healthcare products Regulatory Agency to ensure safe and effective use
Vaccine Management System
Community Pharmacy Vaccination
Governance, Handling & Preparation in GP
MHRA response to Irish authorities’ action to temporarily suspend the AstraZeneca COVID-19 Vaccine
Additional UK Resources
intended for healthcare staff involved in delivering the programme. It includes detailed information on:
- the background of the programme
- the vaccines (as they become available)
- vaccine recommendations and eligibility
- contraindications and precautions
- vaccine administration issues
GOV.UK Resource Page : https://www.gov.uk/government/collections/covid-19-vaccination-programme
COVID-19 Vaccination Training
All vaccinators must be registered health care professionals. Health care assistants may support vaccinators including post vaccination observation but may not administer the vaccine as part of this service.
All vaccinators should complete the COVID-19 vaccinator competency assessment tool Any training needs identified by the COVID-19 vaccinator competency assessment tool should be addressed. Copies of the assessments should be held in the practice. Additional training and information is available on the PHA website.
All vaccinators should complete the e-learning for health module on COVID-19.
RCUK’s expert anaphylaxis group is currently updating the anaphylaxis guidelines for 2021. In light of the current mass vaccination programme they have provided updated information for use in any vaccination setting to give clear guidance to healthcare professionals involved. We have also produced a poster of the algorithm for the management of anaphylaxis in the vaccination setting.
Running a vaccination clinic
Resources for Running a Clinic
Larger or offsite clinics
Our colleagues in regional emergency planning want to ensure that the emergency services, DfI Roads and councils are aware of the locations of larger or off-site COVID-19 vaccination clinics in case there are steps that can be taken to aid the clinics or if you need emergency assistance, for example:
o If you need to seek help from NIAS e.g. anaphylaxis
o If you need to seek help from PSNI re traffic issues or other problems
o So DfI Roads can consider their winter gritting programme in these areas
HSCB would be grateful if you would let your PSM know as soon as possible please about any large or off-site clinics being planned
Leaflets & Posters
The JCVI advises a preference for an mRNA vaccine as the booster dose, irrespective of which vaccine was given in the primary schedule. There is good evidence that these vaccines will provide a strong booster response and all patients should be strongly encouraged to receive an mRNA vaccine as their booster dose. However, there will be cases where mRNA vaccines cannot be offered e.g. due to clinical contraindication, or may be refused, thereby leaving the patient without receiving any...
COVID-19 vaccination in children and young people aged 16 to 17 years: JCVI statement, November 2021 – GOV.UK
The Joint Committee on Vaccination and Immunisation (JCVI) has previously advised: 2 doses of the Pfizer-BioNTech COVID-19 vaccine in children and young people aged 16 to 17 years with an underlying health condition that places them at higher risk from serious COVID-19 (‘at-risk group’) a first dose of Pfizer-BioNTech COVID-19 vaccine for those not in an at-risk group On 19 October 2021 JCVI considered options for offering a second dose to persons aged 16 to 17 years who are not in an...
This SOP describes the process for transporting Pfizer-BioNTech COVID-19 Vaccine (Comirnaty) from PCN Designated Sites to end user location in the same PCN.This SOP is applicable to both Comirnaty, and the original Pfizer-BioNTech Covid-19 vaccine (Regulation 174 product) while stocks remain. During the introduction of the new product, both the Comirnaty and the Regulation 174 product will be in use at the same time. It includes a good diagrammatic representation of this SOP
JCVI advises that a third primary dose be offered to individuals aged 12 years and over with severe immunosuppression in proximity of their first or second COVID-19 vaccine doses in the primary schedule.